NEW YORK (GenomeWeb) – AMD Insight today announced it has exclusively licensed from ArcticDx the commercial rights in Canada for the Macula Risk PGx test.

Macula Risk PGx is a prognostic and pharmacogenetic DNA test for evaluating a patient's risk of progressing to advanced age-related macular degeneration and aids in choosing appropriate vitamin formulations for AMD based on the patient's genetic risk profile.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.